EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access

Recommendations for pharmacogenetic testing in clinical practice guidelines in the US

Daniel L Hertz, Chad A Bousman, Howard L McLeod, Andrew A Monte, Deepak Voora, Lori A Orlando, Rustin D Crutchley, Benjamin Brown, Wrenda Teeple, Sara Rogers, Jai N Patel

American Journal of Health-System Pharmacy · 12.08.2024 · 81 (16) · 672-683

DOI: 10.1093/ajhp/zxae110 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 23.04.2024. Verfasst von Daniel L Hertz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Practice Guidelines as Topic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment. However, clinical uptake of pharmacogenetic testing has been limited. Clinical practice guidelines recommend biomarker tests that the guideline authors deem to have demonstrated clinical utility, meaning that testing improves treatment outcomes. The objective of this narrative review is to describe the current status of pharmacogenetic testing recommendations within clinical practice guidelines in the US. Summary Guidelines were reviewed for pharmacogenetic testing recommendations for 21 gene-drug pairs that have well-established drug response associations and all of which are categorized as clinically actionable by the Clinical Pharmacogenetics Implementation Consortium. The degree of consistency within and between organizations in pharmacogenetic testing recommendations was assessed. Relatively few clinical practice guidelines that provide a pharmacogenetic testing recommendation were identified. Testing recommendations for HLA-B*57:01 before initiation of abacavir and G6PD before initiation of rasburicase, both of which are included in drug labeling, were mostly consistent across guidelines. Gene-drug pairs with at least one clinical practice guideline recommending testing or stating that testing could be considered included CYP2C19-clopidogrel, CYP2D6-codeine, CYP2D6-tramadol, CYP2B6-efavirenz, TPMT-thiopurines, and NUDT15-thiopurines. Testing recommendations for the same gene-drug pair were often inconsistent between organizations and sometimes inconsistent between different guidelines from the same organization.

Conclusion

A standardized approach to evaluating the evidence of clinical utility for pharmacogenetic testing may increase the inclusion and consistency of pharmacogenetic testing recommendations in clinical practice guidelines, which could benefit patients and society by increasing clinical use of pharmacogenetic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingPractice Guidelines as TopicHumansUnited StatesPharmacogeneticsPrecision Medicine

Stichwörter der Autor:innen

clinical practice guidelinesclinical utilitygenetic testingpharmacogenetic testingpharmacogenomics

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
  • Department of Medical Genetics, University of Calgary, Calgary, AB, Canada.
  • Center for Precision Medicine and Functional Genomics, Utah Tech University, St. George, UT, USA.
  • Section of Pharmacology & Medical Toxicology, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
  • Duke Precision Medicine Program, Department of Medicine, Duke University, Durham, NC, USA.
  • Department of Medicine, Duke University, Durham, NC, USA.

Förderung

  • NIGMS NIH HHS
  • NIH

Zitieren

APA

Hertz, D. L., Bousman, C. A., McLeod, H. L., Monte, A. A., Voora, D., Orlando, L. A., Crutchley, R. D., Brown, B., Teeple, W., Rogers, S., & Patel, J. N. (2024). Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. American Journal of Health-System Pharmacy, 81(16), 672-683. https://doi.org/10.1093/ajhp/zxae110

Vancouver

Hertz DL, Bousman CA, McLeod HL, Monte AA, Voora D, Orlando LA, et al. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. American Journal of Health-System Pharmacy. 2024;81(16):672-683. doi:10.1093/ajhp/zxae110

BibTeX
@article{Hertz2024,
  author = {Hertz, Daniel L and Bousman, Chad A and McLeod, Howard L and Monte, Andrew A and Voora, Deepak and Orlando, Lori A and Crutchley, Rustin D and Brown, Benjamin and Teeple, Wrenda and Rogers, Sara and Patel, Jai N},
  title = {Recommendations for pharmacogenetic testing in clinical practice guidelines in the US},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  volume = {81},
  number = {16},
  pages = {672--683},
  doi = {10.1093/ajhp/zxae110}
}
Kostenlos starten →